248 related articles for article (PubMed ID: 28039520)
1. Natalizumab-associated progressive multifocal leukoencephalopathy: successful treatment without plasma exchange and its associated risks.
Maloney E; Molloy A; Al Hussona M; O'Donnell L; Killeen R; McGuigan C
J Neurol; 2017 Feb; 264(2):401-403. PubMed ID: 28039520
[No Abstract] [Full Text] [Related]
2. The 'across the pons' sign: A possible novel radiographic finding in natalizumab-associated progressive multifocal leukoencephalopathy.
Budhram A; Pelikan JB; Kremenchutzky M; Sharma M
J Neurol Sci; 2017 Apr; 375():304-306. PubMed ID: 28320156
[No Abstract] [Full Text] [Related]
3. Application of serum natalizumab levels during plasma exchange in MS patients with progressive multifocal leukoencephalopathy.
Vennegoor A; Rispens T; Van Oosten BW; Wattjes MP; Wondergem MJ; Teunissen CE; Van der Kleij D; Uitdehaag BM; Polman CH; Killestein J
Mult Scler; 2015 Apr; 21(4):481-4. PubMed ID: 25078275
[TBL] [Abstract][Full Text] [Related]
4. Progressive multifocal leukoencephalopathy associated to natalizumab extended dosing regimen.
Hervás JV; Presas-Rodríguez S; Crespo-Cuevas AM; Canento T; Lozano-Sánchez M; Massuet-Vilamajó A; Ramo-Tello C
Neurodegener Dis Manag; 2015 Oct; 5(5):399-402. PubMed ID: 26517599
[TBL] [Abstract][Full Text] [Related]
5. Punctate pattern: A promising imaging marker for the diagnosis of natalizumab-associated PML.
Hodel J; Darchis C; Outteryck O; Verclytte S; Deramecourt V; Lacour A; Zins M; Pruvo JP; Vermersch P; Leclerc X
Neurology; 2016 Apr; 86(16):1516-23. PubMed ID: 27009257
[TBL] [Abstract][Full Text] [Related]
6. [Natalizumab can induce progressive multifocal leucoencephalopathy].
Theódórsdóttir A; Blaabjerg M; Falah M
Ugeskr Laeger; 2014 Aug; 176(35):. PubMed ID: 25293706
[TBL] [Abstract][Full Text] [Related]
7. Fingolimod treatment after natalizumab-related progressive multifocal leukoencephalopathy: three new cases.
Peaureaux D; Pignolet B; Biotti D; Bucciarelli F; Gaina J; Bucur C; Clanet M; Martin-Blondel G; Brassat D
Mult Scler; 2015 Apr; 21(5):671-2. PubMed ID: 25305251
[No Abstract] [Full Text] [Related]
8. High-frequency MRI monitoring should be performed in natalizumab-treated MS patients with higher risk of PML - YES.
Yap SM; McGuigan C
Mult Scler; 2017 May; 23(6):765-767. PubMed ID: 28287039
[No Abstract] [Full Text] [Related]
9. Diagnostic performance of brain MRI in pharmacovigilance of natalizumab-treated MS patients.
Wattjes MP; Wijburg MT; Vennegoor A; Witte BI; Roosendaal SD; Sanchez E; Liu Y; Martins Jarnalo CO; Richert ND; Uitdehaag BM; Barkhof F; Killestein J
Mult Scler; 2016 Aug; 22(9):1174-83. PubMed ID: 26564995
[TBL] [Abstract][Full Text] [Related]
10. Successful management of natalizumab-associated progressive multifocal leukoencephalopathy and immune reconstitution syndrome in a patient with multiple sclerosis.
Schröder A; Lee DH; Hellwig K; Lukas C; Linker RA; Gold R
Arch Neurol; 2010 Nov; 67(11):1391-4. PubMed ID: 20625069
[TBL] [Abstract][Full Text] [Related]
11. Biomarkers identification for PML monitoring, during Natalizumab (Tysabri®) treatment in Relapsing-Remitting Multiple Sclerosis.
Lanza Cariccio V; Bramanti P; Mazzon E
Mult Scler Relat Disord; 2018 Feb; 20():93-99. PubMed ID: 29353737
[TBL] [Abstract][Full Text] [Related]
12. Early onset of natalizumab-related progressive multifocal leukoencephalopathy.
Damasceno A; von Glehn F; Martinez AR; Longhini AL; Deus-Silva L; Brandão CO; Santos LM; Damasceno BP
Mult Scler; 2011 Nov; 17(11):1397-8. PubMed ID: 21900356
[No Abstract] [Full Text] [Related]
13. MRI criteria differentiating asymptomatic PML from new MS lesions during natalizumab pharmacovigilance.
Wijburg MT; Witte BI; Vennegoor A; Roosendaal SD; Sanchez E; Liu Y; Martins Jarnalo CO; Uitdehaag BM; Barkhof F; Killestein J; Wattjes MP
J Neurol Neurosurg Psychiatry; 2016 Oct; 87(10):1138-45. PubMed ID: 27530808
[TBL] [Abstract][Full Text] [Related]
14. Progressive multifocal leukoencephalopathy and granule cell neuronopathy with novel mutation flanking VP1 C-terminus in natalizumab-extended interval dosing.
Rempe T; Wang Q; Wu Q; Ballur Narayana Reddy V; Newcomer Z; Miravalle A; Mao-Draayer Y
Neurol Neuroimmunol Neuroinflamm; 2020 May; 7(3):. PubMed ID: 32198230
[No Abstract] [Full Text] [Related]
15. Influenza vaccination increases anti-JC virus antibody levels during treatment with Natalizumab: Case report.
Miranda Acuña JA; Weinstock-Guttman B
Mult Scler Relat Disord; 2016 Sep; 9():54-5. PubMed ID: 27645344
[TBL] [Abstract][Full Text] [Related]
16. Do we have enough evidence for recommending therapeutic plasma exchange for patients with natalizumab-associated progressive multifocal leukoencephalopathy?
Pham HP; Raju D; Schwartz J
J Clin Apher; 2018 Jun; 33(3):452-453. PubMed ID: 29446163
[No Abstract] [Full Text] [Related]
17. Natalizumab treatment of multiple sclerosis: new insights.
Delbue S; Comar M; Ferrante P
Immunotherapy; 2017 Jan; 9(2):157-171. PubMed ID: 28004598
[TBL] [Abstract][Full Text] [Related]
18. The utility of FDG-PET imaging in distinguishing PML-IRIS from PML in a patient treated with natalizumab.
Baheerathan A; McNamara C; Kalam S; Rane N; Barwick TD; Grote H; Nicholas R
Neurology; 2018 Sep; 91(12):572-573. PubMed ID: 30224501
[No Abstract] [Full Text] [Related]
19. Assessing understanding of individual risk and symptoms of progressive multifocal leukoencephalopathy in patients prescribed natalizumab for multiple sclerosis.
Rath L; Vijiaratnam N; Skibina O
Intern Med J; 2017 Feb; 47(2):194-199. PubMed ID: 27862809
[TBL] [Abstract][Full Text] [Related]
20. Natalizumab for Multiple Sclerosis: A Case in Point for the Impact of Translational Neuroimmunology.
Shirani A; Stüve O
J Immunol; 2017 Feb; 198(4):1381-1386. PubMed ID: 28167648
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]